Vistagen announces key regulatory update on ph94b for the acute treatment of social anxiety disorder

South san francisco, calif.--(business wire)--vistagen therapeutics, inc. (nasdaq: vtgn), a late clinical-stage, central nervous system (cns) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other cns disorders, announced today a key regulatory update on its palisade phase 3 program for ph94b for the acute treatment of anxiety in adults with social anxiety disorder (sad). the u.s. food and drug administration (fda
VTGN Ratings Summary
VTGN Quant Ranking